atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
Pharma marketing is constantly changing and #AI is helping to reshape how brands connect with their audiences.
Discover Medico Digital top 5 #AI predictions and learn how harnessing the power of AI can boost your marketing strategy. Read more here.
Luscii provides the tools for patient and professional to keep an eye on the recovery while checking vital signs and symptoms to signal deteriorations and intervene timely in case of need.
Read more here.